Abstract Number: 1537 • ACR Convergence 2025
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment strategies for severe B-cell driven autoimmune diseases (AID) like Systemic Lupus erythematosus (SLE), Systemic…Abstract Number: 1519 • ACR Convergence 2025
Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
Background/Purpose: Cenerimod is a highly selective S1P1 receptor modulator which is undergoing trials for potential therapeutic benefits in autoimmune disease, including Systemic Lupus Erythematous (SLE).…Abstract Number: 1495 • ACR Convergence 2025
Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE
Background/Purpose: The Physician Global Assessment (PGA) is used to measure disease activity on a 0–10 scale for many pediatric rheumatic conditions. However, the thresholds at…Abstract Number: 1478 • ACR Convergence 2025
Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs. Cognitive dysfunction (CD) is a common but often underestimated complication in…Abstract Number: 1295 • ACR Convergence 2025
Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Background/Purpose: Neuropsychiatric involvement in Systemic Lupus Erythematosus (NPSLE) is a major cause of morbidity and mortality, particularly among children who are still developing neurologically. Despite…Abstract Number: 1232 • ACR Convergence 2025
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Background/Purpose: Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health related bodily…Abstract Number: 1044 • ACR Convergence 2025
Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Background/Purpose: Hydroxychloroquine is a cornerstone in the treatment of Systemic Lupus Erythematosus (SLE), while corticosteroids and immunosuppressive agents are employed for moderate to severe disease…Abstract Number: 0937 • ACR Convergence 2025
MRL-lpr Mice Display Altered Nociception: A new model for lupus peripheral neuropathy
Background/Purpose: Of the 19 ACR case definitions for NPSLE, seven involve the peripheral nervous system. MRL/lpr mice spontaneously develop anti-dsDNA antibodies, nephritis, and skin disease,…Abstract Number: 0667 • ACR Convergence 2025
Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Background/Purpose: In May 2025, ACR released updated recommendations for the management of LN2. Notably, since the previous guidelines update in 2012, the FDA has approved…Abstract Number: 0644 • ACR Convergence 2025
Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Background/Purpose: Fatigue, musculoskeletal pain, and joint stiffness are common manifestations of SLE, presenting considerable treatment challenges, particularly in addressing chronic fatigue. Dapirolizumab pegol (DZP) is…Abstract Number: 0623 • ACR Convergence 2025
Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Evidence from high-income countries suggests that socioeconomic status (SES) and environmental…Abstract Number: 0607 • ACR Convergence 2025
Age at Diagnosis of SLE has Increased in a United States Longitudinal Cohort
Background/Purpose: The demographics of our lupus cohort have shifted over the decades towards an older population. While much of the shift can be attributed to…Abstract Number: 0851 • ACR Convergence 2025
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…Abstract Number: 0772 • ACR Convergence 2025
Redefining When to Biopsy the Kidney in Patients with SLE
Background/Purpose: Current ACR, EULAR and KDIGO guidelines recommend kidney biopsy in SLE patients with urine protein to creatinine (UPCR) ratio of >= 0.50 g/g. However,…Abstract Number: 0188 • ACR Convergence 2025
Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data
Background/Purpose: A lack of knowledge surrounding SLE has been identified as a main challenge for patients, particularly those seeking a diagnosis or recently diagnosed. Subsequently,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 181
- Next Page »
